Q32 Bio prices $18.25/share offering of 6M shares and pre-funded warrants; net proceeds ~$187.6M

Q32 Bio Inc.

Offering of 6,027,399 shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499.
Net proceeds estimated at $187.6M (or $215.8M if underwriters' option exercised in full).
Proceeds for working capital, research, clinical development, and commercialization of bempikibart.
Underwriters: Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer; close expected July 16, 2026.
Pre-funded warrants exercisable at $0.0001/share, subject to ownership limits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.